Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA401098
Max Phase: Preclinical
Molecular Formula: C42H47N5O8
Molecular Weight: 749.87
Molecule Type: Small molecule
Associated Items:
ID: ALA401098
Max Phase: Preclinical
Molecular Formula: C42H47N5O8
Molecular Weight: 749.87
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1ccc(CCNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)OC(C)(C)C)cc1
Standard InChI: InChI=1S/C42H47N5O8/c1-42(2,3)55-41(53)47-35(23-30-25-44-33-12-8-7-11-32(30)33)40(52)45-34(22-27-13-16-28-9-5-6-10-29(28)21-27)39(51)46-36(24-37(48)49)38(50)43-20-19-26-14-17-31(54-4)18-15-26/h5-18,21,25,34-36,44H,19-20,22-24H2,1-4H3,(H,43,50)(H,45,52)(H,46,51)(H,47,53)(H,48,49)/t34-,35-,36-/m0/s1
Standard InChI Key: MFUSEKCCGCHOBJ-KVBYWJEESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 749.87 | Molecular Weight (Monoisotopic): 749.3425 | AlogP: 4.81 | #Rotatable Bonds: 16 |
Polar Surface Area: 187.95 | Molecular Species: ACID | HBA: 7 | HBD: 6 |
#RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 4.08 | CX Basic pKa: | CX LogP: 4.87 | CX LogD: 1.76 |
Aromatic Rings: 5 | Heavy Atoms: 55 | QED Weighted: 0.08 | Np Likeness Score: -0.17 |
1. Low CM, Vinter JG.. (2008) Rationalizing the activities of diverse cholecystokinin 2 receptor antagonists using molecular field points., 51 (3): [PMID:18201065] [10.1021/jm070880t] |
Source(1):